Modulation of ex-vivo uterine contraction by the methanol leaf extract of *Alchornea laxiflora* Benth. (Euphorbiaceae) and preliminary spectrometric identification of associated secondary metabolites

**Background:** The leaves of *Alchornea laxiflora* are traditionally used in the south of Nigeria to prevent preterm births.

**Aim:** This study was designed to investigate the activity of *A. laxiflora* on uterine contractility.

**Setting:** The leaves of the plant were collected from forests in Egor, Benin City, Nigeria.

**Methods:** The leaves were cleaned and extracted in methanol. The extract (0.005 mg/mL–3.5 mg/mL) was tested on spontaneous uterine contraction and on oxytocin-induced contraction in normal and Ca²⁺-free media. The plant extract (0.0035 mg/mL, 0.035 mg/mL, 0.35 mg/mL and 3.5 mg/mL) was tested on high KCl-induced uterine contractions (80 mM). The plant extract (3.5 mg/mL) was also studied in the presence of amiodarone and glibenclamide in separate experiments. Mass spectrometric analysis was additionally performed on the plant extract in order to identify significant secondary metabolites that may have contributed to the activity of the plant.

**Results:** The plant extract inhibited spontaneous, oxytocin and high KCl-induced uterine contractions and also significantly inhibited (*p < 0.01*) oxytocin-induced uterine contraction in Ca²⁺-free medium. The plant extract significantly inhibited (*p < 0.01* and *p < 0.05*) oxytocin’s amplitude in the presence of amiodarone and glibenclamide, respectively. Secondary metabolites belonging to classes of fatty acids, glycols, terpenes, flavonoid glycosides and porphyrins were identified.

**Conclusion:** *Alchornea laxiflora* inhibited mouse uterine contractility possibly through interaction with potassium and calcium channels. Of the known metabolites identified, 3-deoxy-arabino-hept-2-ulosonic acid, 17-hydroxyingenol and phaeophorbide-a methyl inhibit uterine contractility and may contribute to the activity of *A. laxiflora* in utero.

**Introduction**

Uterine contractions are involved in preterm labour (PTL) and dysmenorrhoea. Preterm labour, which leads to preterm births (PTBs), is a major cause of perinatal mortality and morbidity (Goldenberg 2002; Goldenberg et al. 2008). Premature infants are highly susceptible to potentially life-threatening complications, which include, but are not limited to, jaundice, hypoglycaemia, hypothermia, infection and respiratory distress syndrome (Steer & Flint 1999). Although some improvements in neonatal survival rates because of improved neonatal care have been observed in recent years, the incidence of PTB itself has seen little improvements (Bocking 1998). Preterm birth originates from premature uterine contractions and is still one of the major obstetrical problems (Maltaris et al. 2006). Several drugs have been used as tocolytics and they include β-adrenoceptor mimetics, calcium antagonists, prostaglandin (PG) inhibitors and alcohol (Keirse 2003). Tocolysis (pharmacological inhibition of uterine contractility) aids in counteracting PTL and postponing delivery and is still the current mainstay of PTL management. Use of tocolytics is an important intervention as it enables delivery to be delayed long enough for transfer of the mother to a specialist tertiary centre or for corticosteroids to be administered to the mother which promotes maturation of foetal lung (Goldenberg 2002). However, the wide range of tocolytics in

**How to cite this article:** Bafor, E.E., Nyogu, J.K., Elvis-Offiah, U.B., Amaechina, F., Ofeimun, J., Ayinde, B. et al, 2018, ‘Modulation of ex-vivo uterine contraction by the methanol leaf extract of Alchornea laxiflora Benth. (Euphorbiaceae) and preliminary spectrometric identification of associated secondary metabolites’, *Journal of Medicinal Plants For Economic Development* 2(1), a33. https://doi.org/10.4102/jomped.v2i1.33

**Copyright:** © 2018. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
The failure rate of NSAIDs falls between 20% are intolerant to PG inhibitors (Campbell & McGrath 1997). from dysmenorrhea have been reported to respond poorly or a reasonable percentage (about 15%) of women who suffer from dysmenorrhea have high levels of PGs, which are hormones that can mediate uterine contractility, causing cramping abdominal pain (Marjoribanks et al. 2010). Prostaglandins are allegedly released from disintegrating cells during endometrial sloughing, which results in myometrial hypercontractility that then leads to ischaemia and hypoxia of the uterine muscle and, ultimately, pain (Dawood 1988). The most common treatment for primary dysmenorrhea (PD) (which is dysmenorrhea with no known pathology) includes non-steroidal anti-inflammatory drugs (NSAIDs) that combat menstrual pain by reducing intrauterine pressure and inhibiting the enzyme necessary for synthesis of prostaglandin F2 alpha (PGF$_\alpha$), leading to reduced levels in menstrual fluid. However, a reasonable percentage (about 15%) of women who suffer from dysmenorrhea have been reported to respond poorly or are intolerant to PG inhibitors (Campbell & McGrath 1997). The failure rate of NSAIDs falls between 20% and 25% (Dawood 1995), and is often contraindicated in some women (Taylor, Miaskowski & Kohn 2002). Non-steroidal anti-inflammatory drugs have long-term adverse effects which include disorders of the liver, kidney and digestive systems (Liu et al. 2011). Many women have therefore resorted to alternative therapies including non-pharmacologic therapies in order to manage their menstrual discomfort (Campbell & McGrath 1997; Ogunfowokan & Babatunde 2010; Ou et al. 2012). Oral contraceptives (OCPs) have also been used to manage dysmenorrhea by suppressing ovulation and causing a thinned endometrial lining that results in reduced menstrual fluid volume, reduced amount of PG produced and consequently reduction of uterine contractions and therefore pain (Creatsas et al. 1990). However, OCPs can cause side effects, including nausea and water retention, and are contraindicated in women who intend to get pregnant (Hendrix & Alex 2002). Surgical interruption of the pelvic nerve pathways has also been used in women, but the long-term efficacy of this method lacks evidence and it is not a commonly-accepted procedure (Proctor et al. 2010). The limitations associated with these conventional treatments have made herbal medicines feasible alternatives for the treatment of PD (Park et al. 2014). Many patients who failed to respond to conventional PD treatments have been treated with herbal medicines (Chen et al. 2006; Proctor & Murphy 2001).

Medicinal plants have been a valuable source of therapeutic agents, and still many of today’s drugs are plant-derived natural products or their derivatives (Kinghorn et al. 2011; Newman & Cragg 2012). Traditional cultures worldwide depend on herbal remedies for different conditions in menstrual disorders, pregnancy, birth and post-partum care. This, therefore, makes scientific investigation and documentation of traditional knowledge of medicinal plants a crucial event, which assists chemists and pharmacologists with starting points for ‘targeted’ analysis, discovery of novel therapies and natural drugs for the treatment of pregnancy and uterine-related issues (Gruber & O’Brien 2011). For drug discovery targeting dysfunctional labours, medicinal plants with oxytocic or uterine stimulating activities are of significant interest, while for PTLs, those with uterine relaxing activities are sought. Similarly, use of herbal medicines in dysmenorrhea has received some attention (Mirabi et al. 2014; Van Andel et al. 2014), which signifies the importance in the search for new remedies from medicinal plants. The tropical plant, Alchornea laxiflora (AL) (Benth) Pax and Hoffman, of the Euphorbiaceae family, is one of such medicinal plants used by traditional healers in the south of Nigeria for managing uterine contractility, particularly in the prevention of miscarriages (personal communication with traditional healer Mr Eyohan). It is called Uwerriotan by Edo natives, Ulubo in the Igbo language and Ijan or Opoto in the Yoruba language, Nigeria. It is a broad-leaved shrub that sheds its leaves annually and grows to a height of about 6 m–10 m. It can be found abundantly in Nigeria, Cameroon, in DR Congo, throughout East Africa and in Zimbabwe (Burkill 1994). The stems, especially the branches, are used in Nigeria as chew-sticks and the leaves are used to preserve cola nut in Nigeria. Other traditional use includes the management of piles, dysentery, malaria, eczema, cough and high fever (Jayeoba, Ijeomah & Ogara 2012). The decoctions of the leaves of AL have been reported to have antimicrobial effects (Oloyede et al. 2010), antioxidant activity (Farombi et al. 2003), hepatoprotective effects (Oloyede et al. 2011) and have been shown to exert a progestosterone-like effect (Bafor et al. 2016). For PTL prevention, the leaves of AL are collected fresh, preferably at dawn and dusk, washed and squeezed into a glass full of water. The mixture is then filtered and mixed with ‘calabash chalk’ or ‘calabash clay’, often referred to as ‘eko’ in Nigeria, and the concoction is taken twice daily (morning and evening) after conception for a period of six months (personal communication with traditional healer Mr Eyohan). In the search for potential targets for new therapies in managing PTL and dysmenorrhea, this study was aimed at investigating the activity of the plant AL on
uterine contractility and to additionally investigate possible mechanisms of action. This study is also aimed at identifying significant secondary metabolites present in the plant that may have contributed to the plant’s biological activities.

**Materials and method**

**Plant material**

Fresh leaves of *AL* were collected from Egor, 6.3350°N 5.6038°E Benin City in Edo state, Nigeria, in April 2015, with an average humidity of 75% and an average temperature of 35°C. Identification was done by Dr H.A. Akinnibosun of the Department of Plant Biology and Biotechnology, University of Benin, Nigeria, and authenticated by Prof. B.A. Ayinde of the Department of Pharmacognosy, University of Benin, Nigeria. A voucher specimen number of UBHe0286 was provided.

**Animals**

Mature non-pregnant female albino mice weighing an average of 25 g ± 0.57 g, aged 4–5 months, were obtained from the animal house, Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Benin, Edo state, Nigeria. The animals were housed in plastic cages at an environmentally controlled room temperature of approximately 27°C ± 5°C and lighting conditions of approximately 11 or 13 h light and dark cycles. Relative humidity ranged from 80% to 85%. The animals were handled as much as possible according to the standards of the Public Health Service Policy on Humane Care and Use of Laboratory Animals (National Research Council 2010; NIH 2015). The animals were maintained on a standard diet of animal pellets and clean tap water.

**Drugs and chemicals**

Methanol (MeOH) of high analytical grade (Pharmatrends, Nigeria) and Tween 80 (Sigma Aldrich, Dorset, UK) were solvents used in this study. Salts for the physiological solution were obtained from BDH Chemicals, England. Other drugs used in the study include oxytocin (OT) (Laborate Pharmaceuticals, Haryana, India), amiodarone (AM) and glibencamide (GLB) (Sigma Aldrich) and diethylstilboesterol (Sigma Aldrich). For the mass spectrometric experiments, MeOH, dichloromethane (DCM), acetonitrile (MeCN) and formic acid were purchased (Fisher Scientific, Hemel Hempstead, UK). All reagents were of analytical grade.

**Extraction of the plant material**

The collected leaves were cleaned and freed of debris before being shade-dried for two weeks. The dried leaves were then grounded using a milling machine (Christy Norris, England). The powdered samples were kept in airtight containers and stored in the refrigerator at 4°C. The powdered material (855.24 g) was subsequently extracted in MeOH using a Soxhlet apparatus. Exhaustive extraction was performed for 48 h and the resulting solution was filtered and concentrated in a rotary evaporator set at 40°C. The concentrate obtained was dried in an oven at 40°C and the extract weight was determined to be 122.3 g (percentage yield was 14.3% w/w). The extract was then stored in airtight containers and kept in the refrigerator (−4°C) till needed.

**Contractility studies**

**Uterine tissue preparation**

Each mouse (four animals per protocol) was administered 1.0 mg/kg diethylstilboesterol (DES) orally constituted in Tween 80 and distilled water (1:1), 24 h prior to the day of experiments. Oral administration was done using a feeding syringe. Dose and route of DES administration had been previously determined in our laboratory to effectively induce oestrus. On the day of the experiment, vaginal smears were obtained and prepared as previously described (Caligioni 2009; Cora, Kooistra & Travlos 2015). Briefly, with the aid of a Pasteur pipette (0.1 mm), the vaginal smears were collected, fixed with ethanol and stained with a drop of Gentian violet. The smears were then observed under a microscope using a ×10 objective lens in order to ascertain the oestrus stage animals in pro-oestrus and oestrus stages were selected and humanely killed by cervical dislocation and the uterine horns were immediately excised and placed into a Petri dish containing previously warmed and aerated physiological salt solution. The uterine tissues were cleaned of connective tissues and one horn was dissected into half to obtain a segment of the uterine horn. Tissue lengths of approximately 1 mm–2 mm each were obtained. The uterine segment was then mounted in a warmed 10 mL organ bath maintained at 37°C and containing aerated physiological solution. The physiological salt solution used was of the following composition in M: NaCl 154.00, NaHCO3 5.95, D-glucose 2.78, KCl 5.63 and CaCl2·2H2O 2.05 (Bafor, Obasighbon & Itamaomon 2015).

**Experimental protocol**

The uterine tissues were mounted in organ baths and equilibrated under resting tensions of 4.90 mN for 30–45 min or until regular contractions were obtained (time duration used was dependent on when regular contractions were obtained) (Sukwan, Wray & Kupittayanant 2014). The force and frequency of uterine contractions in the longitudinal muscle layers were measured using a 7003E-isometric force transducer (Ugo Basile, Varise, Italy) connected to a 17 400 data capsule digital recorder with an inbuilt bridge amplifier (Ugo Basile).

**Experiment on the effect of extract on spontaneous uterine contraction**

The cumulative effect of the extract on uterine smooth muscle contractility was investigated (Bafor et al. 2013). Concentration–response relationships were obtained at 0.005 mg/mL–3.5 mg/mL. The concentration used had been predetermined in our laboratory as concentrations covering the range of effects of the extract. A contact time of 3 min was allowed following each concentration of
extract administered. After each set of administration, the tissues were washed three times and a washout period minimum of 10 min was allowed for the tissue to recover before the next administration (Bafor et al. 2017).

**Experiment on the effect of extract on oxytocin-induced uterine contraction**

The effect of the extract on OT-induced uterine contraction was investigated. This was done by first performing a concentration response to OT (0.00017 ng/mL–4.98 ng/mL) in the absence of the extract, which was then repeated in the presence of cumulative sub-maximum concentrations of the extract at 0.35 mg/mL and 3.5 mg/mL at 5 min each. Conversion of OT from international units (IUs) to milligram is 16.6 µg/mL (World Health Organization recommendation, where 10 IU = 16.6 µg/mL (World Health Organization 2016)).

**Experiment on high potassium chloride-induced uterine contractility**

The activity of the extract on high KCl (80 mM)-induced tonic contraction was investigated. KCl (80 mM) was added to the bath containing the uterine tissues and left in contact for 5 min, and without washing, cumulative concentrations of the extract (0.0035 mg/mL–3.5 mg/mL) were determined.

**Experiment on the effect of the extract in Ca²⁺-free medium**

After tissue equilibration for 30 min, the physiological salt solution was changed to one without calcium and containing 0.1 mM of ethylenediaminetetraacetic acid (EDTA). The tissue was then equilibrated in the Ca²⁺-free solution for a further 15 min. After equilibration, OT (0.05 mM) was added and a contact time of 5 min was allowed. Without flushing, the extract (3.5 mg/mL) was added. A contact time of 5 min was allowed for the extract concentration.

**Experiment on interaction of extract with K⁺-channels**

The effect of the extract (3.5 mg/mL) on OT-induced contraction (0.05 mM) was determined in the absence and presence of AM (0.04 mM) and GLB (0.04 mM) – both adenosine triphosphate (ATP)-sensitive K⁺-channel blockers. This was achieved by addition of OT to the tissue bath and this was left in contact for 5 min and without flushing, the extract was added and left for a further 5 min. Without washing, AM or GLB was then added to the bath and the effect was observed for a further 5 min.

**Liquid chromatography–high-resolution Fourier transform mass spectrometry identification of constituents in extract**

Samples were prepared at a concentration of 1 mg/mL in 80:20 MeOH:DCM. A solvent blank was also included. Liquid chromatography–high-resolution Fourier Transform mass spectrometry (LC-HRFTMS) analysis was performed on a Dionex UltiMate-3000 (DIONEX, Sunnyvale, CA, USA) coupled to a Thermo Scientific Exactive Orbitrap system (Thermo Fisher Scientific (Bremen) GmbH, Bremen, Germany). The mass accuracy was set to less than 3.0 ppm. The instrument was externally calibrated according to the manufacturer’s instructions before the run. An ACE C18 column with dimensions of 75 x 3.0 mm from Hichrom Ltd., Reading, UK, was used. Parameters used were as previously described (Bafor et al. 2016). Briefly, 10 µL of the sample was injected from the vial and elution flow rate was set at 300 µL/min with water (A) and MeCN (B), both of which contained 0.1% formic acid. A gradient flow was used, starting with 10% B and increasing to 100% B in 30 min. The mobile phase was maintained for 5 min at 100% B; this was followed by equilibration of the column with 10% B. The resulting data files were divided into positive and negative data sets using ProteoWizard (Kessner et al. 2008) prior to data mining that was performed with the use of MZmine 2.10 (Plusskal et al. 2010). Peak detection was accomplished using the centroid mass detector and a noise level of 1000 was set. The chromatogram builder generated peak lists from the mass lists obtained from the previous step. The minimum time span was 0.2 min, the minimum height was 10 000 intensity and the m/z tolerance was set at 0.0001 m/z or 5 ppm. Chromatogram deconvolution was accomplished using the local minimum search algorithm with the following parameters: threshold (90%), search minimum in retention time (RT) range (0.4 min), minimum relative height (5%), minimum absolute height (10 000 intensity), minimum ratio of peak top or edge (Goldenberg 2002) and peak duration range (0.2–5.0 min). The peak lists were de-isotoped using the isotopic peaks grouper with an m/z tolerance of 0.001 m/z or 5 ppm, RT tolerance of 0.1 min (absolute) and maximum charge of 2. The representative isotope was the most intense. The peak lists were then merged using the alignment function. The weight for m/z and for RT was 20, and the RT tolerance was 5%. The aligned peak lists were gap-filled using the PeakFinder, with an intensity tolerance of 1% and RT tolerance of 0.5 min (absolute) (Macintyre et al. 2014). The adducts were identified together with other complexes that may have formed within the metabolite pool. The chemical formulae of each peak were predicted using the formula prediction tool developed by MZmine. ChemBioFinder version 13 (PerkinElmer Informatics, Cambridge, UK) was used to access hits from the database.

**Data analysis**

The mean frequency and amplitude were computed from contractions occurring at the last 3 min of the phasic contractions using the GraphPad Prism (version 7.03; GraphPad Software Inc, San Diego, CA, USA). Results were obtained as percentages of control applications (control = 100%) where necessary and changes in force (amplitude) or frequency were expressed with respect to control (100%). All data shown were expressed as mean ± standard error of mean (SEM) and n represents the number of animals (in this study, n = 4 animals). Significance was evaluated using appropriate t-tests, and where necessary, one-way analysis of variance with Dunnett’s post hoc test and p values ≤ 0.05 was taken to represent the minimum significance in all cases.

In data sets with sufficient data points, mean log concentration–response curves were analysed by fitting data to a variable slope
logistic equation, using the following equation values: \( Y = \frac{\text{Bottom} + (\text{Top}-\text{Bottom})}{1 + 10^{(\text{LogIC}_{50}-X)\text{HillSlope}}}, \)
where \( Y \) is the response that starts at the bottom and goes to the top in sigmoid shape, \( X \) is the logarithm of concentration and half maximal inhibitory concentration (IC\(_{50}\)) is the concentration that gives a response half way between bottom and top.

**Ethical considerations**

Ethical permission was obtained prior to start of the experiments from the Faculty of Pharmacy Animal Ethics Committee, University of Benin, Nigeria, and the study was provided an approval reference number: EC/FP/016/08.

**Results**

**Vaginal cytology of the experimental animals**

Representative exfoliative vaginal cytology for the stage of the oestrus cycle of animals utilised for this study is presented in Figure 1. The relative prevalence of the cell type was used to ascertain the oestrus phase for each recipient mouse. Typically, animals in the oestrus and pro-oestrus phases were utilised for this study.

**Effect of extract on spontaneous uterine contraction**

Cumulative concentration–response experiments were performed to determine the effects of the extracts on the force and frequency of spontaneous uterine contractions. Response curves were determined for AL (\( n = 5 \)). *Alchornea laxiflora* was observed to inhibit spontaneous uterine contractions at higher concentrations (Figure 2). However, lower concentrations appeared to slightly increase contractility (Figure 2a). Both the amplitude and frequency of spontaneous uterine contractions were inhibited by AL; however, AL appeared to have more effect on the amplitude than on the frequency (Figure 2b).

**Effect of extract on oxytocin-induced uterine contractions**

Experiments were performed to characterise the activities of AL on OT-induced uterine contractions. *Alchornea laxiflora* was observed to inhibit OT-induced uterine contractility. Two concentrations of AL were used for this phase of the study. At the lower concentration of 0.35 mg/mL, no marked inhibition was observed for both amplitude and frequency of contraction, but a reduction of the baseline tension was seen (Figure 3a). However, at 3.5 mg/mL AL, there was a rightward shift in the amplitude and frequency concentration–response curves of OT (Figure 3b and c).

**Effect of extract on high potassium chloride-induced uterine contraction**

Characterisation of the actions of AL to high K\(^+\) solution was performed. The possibility of interaction of AL with extracellular calcium channels involved in high K\(^+\) depolarisation of smooth muscles (Triggle 1987) was investigated. High KCl solution produced a rapid increase in force that was immediately preceded by a decline and rapidly oscillating production of force (Crichton et al. 1993). *Alchornea laxiflora* inhibited high KCl-induced contraction and this inhibition was more pronounced at the concentration of 3.5 mg/mL (Figure 3a). This was observed as a decrease in the amplitude of response elicited by high KCl (Figure 4b).

**Effect of extract in Ca\(^{2+}\)-free medium**

Further experiments were designed to investigate whether AL extract could inhibit internal Ca mobilisation from the sarcoplasmic reticulum (Arrowsmith & Wray 2014; Wray & Arrowsmith 2012). To do so, internal Ca mobilisation was
blocked by utilisation of a Ca-free medium. In a medium containing zero-calcium, AL (3.5 mg/mL) reduced the contractions of OT-induced uterine contractions (Figure 5a).

On analysis, a significant inhibition ($p < 0.01$) by AL on OT-induced contraction (0.005 mM) was observed (Figure 5). *Alchornea laxiflora* reduced the amplitude of OT-induced contractions under these conditions to about 69.9% (Figure 5b).

Effect of extract on oxytocin-induced uterine contractions in the presence of amiodarone, a K$^+$-ATP-dependent channel blocker

A further inhibition of OT-induced (0.05 mM) uterine contraction by AL (3.5 mg/mL) was observed in the presence of AM (0.04 mM) (Figure 6a). This was shown in the bar plots where analysis showed that AL significantly inhibited ($p < 0.01$) OT in the presence of AM (Figure 6b). Oxytocin was reduced by AL to 78.70% of the original amplitude of contraction, which was further reduced to 59.81% in the presence of AM (Figure 6b).

Effect of extract on oxytocin-induced uterine contractions in the presence of glibenclamide, an adenosine triphosphate-dependent K$^+$-channel blocker

This experiment was performed in order to evaluate the specific interactions of AL with K$^+$ channels, ATP-sensitive potassium channels (K$^+_{\text{ATP}}$), and β-adrenoceptors. Therefore, in the presence of AM (a K$^+$-channel and β-adrenoceptor...
blocker) (Zhang et al. 2016) and in the presence of GLB (K\textsuperscript{+}-ATP inhibitor) (Luzi & Pozza 1997), the inhibitory effect of AL on OT was evaluated. In the presence of AM, AL was observed to significantly inhibit \( p < 0.05 \) OT-induced contraction (Figure 7). Similarly, in the presence of GLB, AL significantly inhibited \( p < 0.05 \) OT-induced contraction (Figure 7). In both instances, the original inhibition by AL on OT was further potentiated.

**Mass spectrometric identification of secondary metabolites in the extract**

Significant secondary metabolites that make up the major constituents of AL were identified. The LC-HRFTMS results and database search (using Dictionary of Natural Products) enabled the detection of 18 significant compounds (Tables 1 and 2). Seven compounds were known (Table 1) and 11 were unknown (Table 2). The identified compounds are (1) 4-Amino-4-deoxyarabinose; \( \alpha \)-D-Pyranose-form, Me glycoside, (2) 2-Methyl-1,2,3,4-butanetetrol; (2S,3R)-form, 4-Phosphate, (3) 2-Amino-4,5-dihydroxy-3,4-dimethylpentanoic acid; (2S,3S,4R)-form, \( \gamma \)-Lactone, (4) 3-Deoxy-arabino-hept-2-ulosonic acid, (5) Adipedatol, (6) 17-Hydroxyingenol; 17-Benzoyl, 3-angeloyl, 5-Ac and (7) Phaeophorbide-a; 10-Epimer, 3″-Me ester.

The chromatogram depicted the individual peaks of the identified compounds (Figure 8) and the structures of the known identified compounds are also presented (Figure 9).
2.10E+08  2.00E+08  1.80E+08  1.90E+08  1.70E+08  1.60E+08  1.50E+08  1.40E+08  1.30E+08  1.20E+08  1.10E+08  1.00E+08  9.00E+7  8.00E+7  7.00E+7  6.00E+7  5.00E+7  4.00E+7  3.00E+7  2.00E+7  1.00E+7

Intensity

1-4  15  16  5  6  7  17  18

FIGURE 8: Total ion chromatogram for *Alchornea laxiflora* showing identified metabolites (1–7) and unidentified but detected metabolites (8–18). The identification, molecular formula, molecular weight, mass-to-charge ratio (m/z) and retention time (RT) in minutes are indicated in Tables 1 and 2.

### TABLE 1: Putatively identified compounds in *Alchornea laxiflora*.

<table>
<thead>
<tr>
<th>Compound name</th>
<th>Molecular formula</th>
<th>Molecular weight (g/mol)</th>
<th>m/z</th>
<th>Rt (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-Amino-4-deoxyarabinose; α-D-Pyranose-form, Me glycoside</td>
<td>C₆H₁₃NO₄</td>
<td>163.0843</td>
<td>[M+1]+ 164.0915</td>
<td>1.12</td>
</tr>
<tr>
<td>2-Methyl-1,2,3,4-butanetetrol; (2S,3R)-form, 4-Phosphate</td>
<td>C₅H₁₀O₄P</td>
<td>216.0401</td>
<td>[M-1]- 215.0328</td>
<td>1.14</td>
</tr>
<tr>
<td>2-Amino-4,5-dihydroxy-3,4-dimethylpentanoic acid; (2S,3R)-form, α-Lactone</td>
<td>C₇H₁₂NO₃</td>
<td>159.0896</td>
<td>[M+1]+ 160.0968</td>
<td>1.17</td>
</tr>
<tr>
<td>3-Decox-arabino-hept-2-ulosonic acid</td>
<td>C₇H₁₂O₇</td>
<td>208.0582</td>
<td>[M-1]- 207.0509</td>
<td>1.19</td>
</tr>
<tr>
<td>Adipedatol</td>
<td>C₂₉H₄₈O₂</td>
<td>428.3651</td>
<td>[M+1]+ 429.3724</td>
<td>24.46</td>
</tr>
<tr>
<td>17-Hydroxygingenol; 17-Benzoyl, 3-angeloyl, 5-Ac</td>
<td>C₁₄H₂₁O₉</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>1.16</td>
</tr>
<tr>
<td>Phaeophorbide a; 10-Epimer, 3”-Me ester</td>
<td>C₁₅H₂₃NO₇</td>
<td>404.1046</td>
<td>[M+1]+ 405.1119</td>
<td>1.18</td>
</tr>
<tr>
<td>C₁₆H₂₄N₂O₃</td>
<td>405.1119</td>
<td>[M-1]- 404.1046</td>
<td>[M-1]- 405.1119</td>
<td>1.18</td>
</tr>
<tr>
<td>C₁₅H₂₂N₂O₆</td>
<td>405.1119</td>
<td>[M-1]- 404.1046</td>
<td>[M-1]- 405.1119</td>
<td>1.18</td>
</tr>
<tr>
<td>C₁₃H₂₀NO₅</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>[M-1]- 388.1219</td>
<td>1.16</td>
</tr>
<tr>
<td>C₁₃H₁₈N₂O₇</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>[M-1]- 388.1219</td>
<td>1.16</td>
</tr>
<tr>
<td>C₁₃H₁₇NO₃</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>[M-1]- 388.1219</td>
<td>1.16</td>
</tr>
<tr>
<td>C₁₃H₁₉NO₉</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>[M-1]- 388.1219</td>
<td>1.16</td>
</tr>
<tr>
<td>C₁₃H₁₈NO₁₀</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>[M-1]- 388.1219</td>
<td>1.16</td>
</tr>
<tr>
<td>C₇H₁₃NO₄</td>
<td>175.0839</td>
<td>[M+1]+ 176.0912</td>
<td>1.15</td>
<td></td>
</tr>
<tr>
<td>C₁₆H₃₀N₂O₄</td>
<td>412.2589</td>
<td>[M+1]+ 413.2662</td>
<td>32.71</td>
<td></td>
</tr>
<tr>
<td>C₄₃H₅₈NO₃</td>
<td>684.4288</td>
<td>[M+1]+ 685.4360</td>
<td>35.78</td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 2: Unidentified compounds in *Alchornea laxiflora*.

<table>
<thead>
<tr>
<th>S/N</th>
<th>Predicted molecular formula</th>
<th>Double bond equivalence</th>
<th>Molecular weight (g/mol)</th>
<th>m/z</th>
<th>Rt (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>C₅H₅N₂O₄</td>
<td>6.5</td>
<td>226.0688</td>
<td>[M-1]- 225.0616</td>
<td>1.12</td>
</tr>
<tr>
<td>9</td>
<td>C₅H₅N₂O₄</td>
<td>2.5</td>
<td>175.0839</td>
<td>[M+1]+ 176.0912</td>
<td>1.15</td>
</tr>
<tr>
<td>10</td>
<td>C₅H₅N₂O₄</td>
<td>10.5</td>
<td>378.0930</td>
<td>[M-1]- 377.0857</td>
<td>1.16</td>
</tr>
<tr>
<td>11</td>
<td>C₅H₅N₂O₄</td>
<td>7.0</td>
<td>388.1219</td>
<td>[M-1]- 387.1146</td>
<td>1.16</td>
</tr>
<tr>
<td>12</td>
<td>C₅H₅N₂O₄</td>
<td>6.0</td>
<td>369.1426</td>
<td>[M-1]- 368.1349</td>
<td>1.16</td>
</tr>
<tr>
<td>13</td>
<td>C₅H₅N₂O₄</td>
<td>7.0</td>
<td>405.1119</td>
<td>[M-1]- 404.1046</td>
<td>1.18</td>
</tr>
<tr>
<td>14</td>
<td>C₅H₅N₂O₄</td>
<td>2.0</td>
<td>175.0838</td>
<td>[M+1]+ 176.0911</td>
<td>1.19</td>
</tr>
<tr>
<td>15</td>
<td>C₅H₅N₂O₄</td>
<td>15.5</td>
<td>488.2028</td>
<td>[M-1]- 487.1956</td>
<td>7.46</td>
</tr>
<tr>
<td>16</td>
<td>C₅H₅N₂O₄</td>
<td>3.5</td>
<td>328.2244</td>
<td>[M-1]- 327.2172</td>
<td>11.09</td>
</tr>
<tr>
<td>17</td>
<td>C₅H₅N₂O₄</td>
<td>5.0</td>
<td>412.2589</td>
<td>[M+1]+ 413.2662</td>
<td>32.71</td>
</tr>
<tr>
<td>18</td>
<td>C₅H₅N₂O₄</td>
<td>15.5</td>
<td>684.4288</td>
<td>[M+1]+ 685.4360</td>
<td>35.78</td>
</tr>
</tbody>
</table>

Note: Double-bond equivalence (DBE) indicates number of rings and double bonds in the structure where 1 ring = 1 DBE; m/z = mass to charge ratio.
Discussion

*Alchornea laxiflora* has been shown in this study to inhibit spontaneous and OT-induced uterine contraction of the non-pregnant uterus. The uterus is chiefly made up of smooth muscle cells and is characterised by spontaneous and rhythmic oscillations of contractions and relaxations (Kelly 1962; Pehlivanoğlu, Bayrak & Doğan 2013). This uterine activity of myogenic origin is observed even in denervated preparations (Bulletti et al. 1993). In the non-pregnant uterus, contractions act to expel menstrual debris in the early follicular phase, in propelling spermatozoa from the cervix to the distal tube ends (de Vries et al. 1990), and assist in the return of oocytes or embryos to the uterine cavity. Uterine contractility also favours proper placement of concepti in the uterine cavity and is therefore important in implantation (Bulletti et al. 2000). Abnormal uterine contractility (dyskinesia) may result in pelvic pain (dysmenorrhea), abortion and PTL (Bulletti et al. 1993; Kelly 1962). It has been shown that an increase in frequency of uterine contractions occurs during the follicular phase followed by a decrease during the luteal phase of the menstrual cycle (Bulletti et al. 1993; Lyons et al. 1991). However, the amplitude of uterine contractions increases during the luteal phase and is subsequently decreased at the time of menstruation (Bulletti et al. 2000). The stage of cycle used in this study was the late follicular and ovulation stages where frequency of uterine contractions is high. We observed an initial increase in tension that was attenuated with higher concentrations of the extract resulting in a decrease in amplitude and frequency even in conditions where frequency of contractions is expectedly higher than other cycle phases. Spontaneous contractions have been attributed primarily to the influx of Ca\(^{2+}\) (Shmigol, Eisner & Wray 1998; Wray et al. 2003) from the intracellular and extracellular spaces (Floyd & Wray 2007). This therefore suggests a possible inhibition of calcium influx by AL. Stimulation of OT receptor by OT activates the phospholipase C system, which, in turn, leads to the eventual mobilisation of Ca\(^{2+}\) from intracellular stores; this is considered the canonical pathway for OT stimulation of uterine contractility (Arrowsmith & Wray 2014; Wray 2007). However, Ca\(^{2+}\) from extracellular space also contributes to the rise in [Ca\(^{2+}\)], stimulated by OT. Contribution of Ca\(^{2+}\) from extracellular space appears to occur via voltage-operated calcium channels (VOCCs) which are also essential for the phasic, spontaneous uterine contractions (Wray et al. 2001). The inhibition of OT by AL additionally supports AL inhibition of Ca\(^{2+}\) but also proposes interaction of AL with the second messenger metabolites involved in OT’s activity. That AL inhibits spontaneous and OT-induced uterine contractility, the inhibition of Ca\(^{2+}\), and the proposed interaction with the second messenger metabolites involved in OT’s activity.
contractions similarly suggests inhibition of a common signalling pathway that appears to be Ca\(^2+\) and more likely inhibition of Ca\(^2+\) through VOCCs, as the operation of VOCCs is shared in both spontaneous and OT-induced uterine contractions. In order to investigate this possibility further, the effect of AL on depolarised tissues was studied. This was achieved in the presence of high KCl which opens L-type VOCCs (Granger, Hollingsworth & Weston 1986; Niedergerke 1996), resulting in a sustained depolarisation of the tissues (Little, Teaf & Hurwitz 1985). Again, the depolarisation by KCl was inhibited by AL in this study, further supporting the interaction of AL with Ca\(^2+\).

Importantly, Ca\(^2+\) contribution in uterine contractility involves the intracellular stores as well as the VOCCs. In order to examine the possibility of AL inhibiting the intracellular release of Ca\(^2+\), the activity of AL was examined in Ca\(^2+\)-free medium. In the absence of Ca\(^2+\) in the medium, AL inhibited the effect of OT where Ca\(^2+\) arises principally from intracellular stores (Kupittayanant, Luckas & Wray 2002; Luckas, Taggart & Wray 1999). This suggests a possible activity of AL on both L-type VOCCs and intracellular Ca\(^2+\) stores and also supports interaction with inositol triphosphate (IP\(_3\)), a second messenger involved in OT’s contractility by regulating intracellular Ca\(^2+\) release (Stepien & Ziecik 2002; Zingg & Laporte 2003). In order to investigate possible involvement of K\(^+\) channels on AL’s activity, the extract was tested on OT’s effect in the presence of K\(^+\)-channel blockers (AM and GLB). Potassium channels exist in the myometrium and function to neutralise depolarisations and prevent generation of action potentials when necessary (Piedras-Renteria, Stefani & Toro 1991). Amiodarone and GLB have been reported to inhibit ATP-sensitive K\(^+\) channels (K\(^+\)\(_{ATP}\)) (Grover & Garlid 2000; Holmes et al. 2000). Opening of K\(^+\)\(_{ATP}\) channels in smooth muscle cells would lead to hyperpolarisation of the membranes and eventual relaxation (Grover & Garlid 2000). Therefore, blockade of K\(^+\)\(_{ATP}\) would prevent relaxation and potentiate depolarisation. The effect of AL on OT in the presence of either AM or GLB was more potent than when tested alone, suggesting that in addition to blockade of Ca\(^2+\) channels AL also activates opening of K\(^+\) channels in the myometrium. Earlier studies had described a progesterone-like effect of AL (Bafor et al. 2016). Progesterone promotes inhibition of the frequency of uterine contractility (Bulletti et al. 2000) and is also necessary for maintaining uterine quiescence during pregnancy (Gellersen, Fernandes & Brosens 2009). Progesterone is also known to inhibit Ca\(^2+\) channels and activate K\(^+\) channels (Soloff et al. 2011) and therefore supports the observed effect of AL in this study.

Mass spectrometric analysis led to the identification of seven secondary metabolites and others were unknown. Of those identified some knowledge regarding their biological activity and possible involvement in the activity of AL is described. The metabolite 4-Amino-4-deoxyarabinose is a pentosamine. Pentoses range from complex carbohydrates such as the antibiotic everninomicin to simple sugars such as L-arabinose and L-xyllose. Several biological activities of pentose compounds have been reported, ranging from antimicrobial to anticancer activities (Forsman & Leino 2011). With regard to their involvement with organs of the reproductive system, not much is known; however, sugars have been reported to regulate some ligand function and sperm motility in mice (Chapman & Barratt 1996). The metabolite 2-methyl-1,2,3,4-butanetetrol, also known as 2-methylenylthritol, is a soluble carbohydrate that is found in certain higher plants and is likely a dephosphorylated form of 2-C-methyl-D-erythritol-4-phosphate (MEP). The form MEP is a central component to the non-mevalonate pathway for isoprenoid synthesis (Witzczak, Whistler & Daniel 1984). As far as contribution to uterine signalling is concerned, no specific relationship has been observed so far. The metabolite 2-amino-4,5-dihydroxy-3,4-dimethylpentanoic acid is an amine acid. Amino acids primarily function as components of proteins and some are considered as essential compounds that must be ingested as they partake and support bodily functions including pain relief (Wu 2009). The exact biological role of 2-amino-4,5-dihydroxy-3,4-dimethylpentanoic acid in uterine function is, however, unknown at this time. The compound 3-deoxy-arabino-hept-2-ulosonic acid is a keto ester (Liu et al. 2002). Keto esters have, however, been reported to inhibit anandamide hydrolase and therefore act as potent fatty acid amide hydrolase (FAAH) inhibitors (Malabu et al. 1992). Fatty acid amide hydrolase is a mammalian integral membrane enzyme that degrades the fatty acid amide family of endogenous signalling lipids, which includes the endogenous cannabinoid anandamide and the sleep-inducing substance oleamide (McKinney & Cravatt 2005). It has been reported that the uterus is a target for cannabinoid ligand-receptor signalling where it functions may be to induce myometrial signalling via the adenylyl cyclase pathway (Das et al. 1995; Dennedy et al. 2004). This therefore suggests a possible contribution of 3-deoxy-arabino-hept-2-ulosonic acid to the activity of AL in this study. Adipedatol is a triterpenoid (Ageta & Shiojima 1968). While there is no direct information on the effect of adipedatol on uterine contractility or function, there are studies that report the effect of triterpenoids on uterine contractility. Vaccaroid A, a triterpenoid from seeds of Vaccaria segetalis, has been reported to stimulate uterine contractility (Morita et al. 1997). Quassin, a triterpenoid from stem bark extract of Quassia amara, was also reported to exhibit reversible antifertility and anti-oestrogenic properties (Raji et al. 2010). Dalsaxin, a triterpenoid glycoside isolated from the root of Dalbergia saxatilis, also stimulated uterine contractility in rats (Uchendu & Leek 1999a, 1999b). It therefore seems that triterpenoids stimulate uterine contractility and adipedatol would not have contributed to the inhibitory effect of AL but may have a role to play in the mild uterine stimulation observed at lower concentrations on spontaneous contractions. The compound 17-hydroxyingenenol is a terpene alcohol (Devappa, Makkar & Becker 2011). Terpene alcohols are commonly used as fragrance and flavour ingredients (Belsito et al. 2008); however, they are known to exert some biological activities as well. For instance, spathulanol, a terpene alcohol from Lepechinia caulescens, was reported to potently inhibit uterine contractility possibly via blockade of VOCCs (Perez-Hernandez et al. 2008). In addition, 17-hydroxyingenenol is known to inhibit phorbol 12,13-dibutyrate (PDBu) binding to protein kinase C (PKC) (Mbwanmo et al. 1996).
Hydroxyingenol actively binds and activates PKC (Blanco-Molina et al. 2001). Protein kinase C belongs to the family of serine or threonine kinases and is known to participate in the regulation of uterine smooth muscle contraction and acts primarily to stimulate uterine contractility (Di Liberto et al. 2003; Kim et al. 2006; Phillippe 1994). Inhibition of PKC by hydroxyingenol may therefore also contribute to the effect of AL in this study. Phaeophorbide-a methyl ester, also detected in AL, has been shown to inhibit spontaneous and OT-induced uterine contractility (Bafor et al. 2013) and may therefore contribute to the effect of AL in this study.

Conclusion

The leaves of *A. laxiflora* have been shown in this study to exert inhibitory effects on uterine contractility. Its activity appears to occur via blockade of extracellular and intracellular calcium channels and may also involve regulation of K-channels. The activity of *A. laxiflora* on uterine contractility has also been suggested to be a contribution of 3-deoxy-arabino-hept-2-ulosonic acid, 17-hydroxyingenol or phaeophorbide-a methyl ester. These compounds may have acted individually or synergistically to effect the inhibitory activity observed. Further studies on identification of the metabolite directly related to the uterine inhibitory activity of *A. laxiflora* are therefore suggested. This study has provided data that the leaves of *A. laxiflora* may present as suitable candidates for drug development in the search for useful alternatives for PTL and dysmenorrhoea.

Acknowledgements

The authors would like to thank Miss I. Okosun for her assistance during the experiments.

Competing interests

The authors declare that they have no financial or personal relationships which may have inappropriately influenced them in writing this article.

Authors’ contributions

E.E.B. conceptualised and designed the study, participated in the experiments, analysed the data and wrote the manuscript. J.K.N. participated in the experiments and data analysis and was involved in the plant collection, preparation and extraction. J.O, F.A. and B.A. were primarily involved in the plant extraction and manuscript writing. U.B.E. and O.O. participated in the uterine contractility experiments. C.V. and R.E. were involved in the mass spectrometric experiments, interpretation of data and contributed in writing the manuscript.

References


